| |
Lifeline BioTechnologies Featured in Medical Newsletter, Diagnostic Imaging Scan
RENO, Nev.--(BW HealthWire)--Nov. 5, 1998--Lifeline BioTechnologies (OTC BB:LBTI) a leader in early breast cancer detection with its proprietary product, First Warning(tm) was featured in the October 28 issue of Diagnostic Imaging Scan(R).
The article highlights First Warning's(tm) groundbreaking technology, a non-invasive breast cancer detection system developed to screen younger women. According to the article, William Reeves, Lifeline's founder, stated, ''There's a big difference between pre- and post-menopausal cancer. Cancer is not an event, it's a process.
''The empirical data would indicate that the milieu for breast cancer is the early childbearing years -- and if you have a technology where you can screen women (at this time), you're way ahead of the game.''
Diagnostic Imaging Scan(R) is a business to business global biweekly newsletter covering the medical imaging market.
Lifeline BioTechnologies, Inc.'s (Lifeline) has developed a non-invasive test for early breast cancer detection. The test is incorporated into a proprietary product called First Warning(tm). In preliminary pilot studies, First Warning(tm) demonstrated great promise in detecting formation of extremely early stage breast lesions, particularly in younger women.
The second product division under Lifeline BioTechnologies is a line of nutritional food supplements packaged and sold under the tradename NATURE'S CREATIONS. These supplements are marketed and directed towards people afflicted with degenerative diseases that are commonly found in the aging population. These diseases include cancer (breast, colon and prostate) cardiovascular, osteoporosis and mental alertness.
For more information on Lifeline BioTechnologies, please visit, lbti.com.
|
|
